Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1826]

Intraperitoneal chemotherapy slows ovarian cancer progression

Dr Helen Mackay - Sunnybrook Research Institute, Toronto, Canada

Intraperitoneal chemotherapy slows ovarian cancer progression ( Dr Helen Mackay - Sunnybrook Research Institute, Toronto, Canada )

Controlled phase III trial of adjuvant combination chemotherapy of gemcitabine...

Prof John P. Neoptolemos - University of Liverpool, Liverpool, UK

Controlled phase III trial of adjuvant combination chemotherapy of gemcitabine and capecitabine, versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma ( Prof John P. Neoptolemos - University of Liverpool, Liverpool, UK )

Phase II study of intraperitoneal versus intravenous chemotherapy following...

Dr Helen Mackay - Sunnybrook Research Institute, Toronto, Canada

Phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer ( Dr Helen Mackay - Sunnybrook Research Institute, Toronto, Canada )

Temozolomide after radiotherapy improves glioma survival

Dr Martin Van Den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands

Temozolomide after radiotherapy improves glioma survival ( Dr Martin Van Den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands )

Oncology for children: what can be done when resources are scarce?

Prof Elizabeth Molyneux - Queen Elizabeth Central Hospital, Blantyre, Malawi

Oncology for children: what can be done when resources are scarce? ( Prof Elizabeth Molyneux - Queen Elizabeth Central Hospital, Blantyre, Malawi )

Relapsed Hodgkin lymphoma in PET positive patients

Dr Graham Collins - Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Relapsed Hodgkin lymphoma in PET positive patients ( Dr Graham Collins - Oxford University Hospitals NHS Foundation Trust, Oxford, UK )

Direct activation of STING in the tumour microenvironment leads to potent and...

Dr Thomas Dubensky - Aduro Biotech, Berkley, USA

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )

Understanding personalised medicine - the e-learning course

Prof Gordon McVie

Understanding personalised medicine - the e-learning course ( Prof Gordon McVie )

Inflammatory microenvironment regulates colorectal cancer progression

Dr Sergei Grivennikov - Fox Chase Cancer Center, Philadelphia, USA

Inflammatory microenvironment regulates colorectal cancer progression ( Dr Sergei Grivennikov - Fox Chase Cancer Center, Philadelphia, USA )

Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors

Dr Shivaani Kummar - Stanford University, Stanford, USA

Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors ( Dr Shivaani Kummar - Stanford University, Stanford, USA )

Chronic lymphocytic leukaemia: Transition to a new era

Prof Stephen Mulligan - Royal North Shore Hospital, Australia

Chronic lymphocytic leukaemia: Transition to a new era ( Prof Stephen Mulligan - Royal North Shore Hospital, Australia )

The role of the microenvironment and novel therapies in CLL

Prof Jan Burger - MD Anderson Cancer Center, Texas, USA

The role of the microenvironment and novel therapies in CLL ( Prof Jan Burger - MD Anderson Cancer Center, Texas, USA )

More from ecancer